# Key role of the endothelium in lung ischemia-reperfusion injury: What the clinician needs to know

**Authors:** Emmanuel BESNIER, Thomas CLAVIER, Jérémy BELLIEN, Jean SELIM

PMC · DOI: 10.1016/j.jhlto.2026.100503 · JHLT Open · 2026-01-29

## TL;DR

This paper explains how damage to the lung's blood vessel lining causes major complications after lung transplants and suggests new ways to protect these vessels.

## Contribution

Highlights the pulmonary endothelium and glycocalyx as central targets in lung ischemia-reperfusion injury and potential therapeutic strategies.

## Key findings

- Endothelial dysfunction during ischemia-reperfusion leads to vascular permeability and pulmonary edema.
- Glycocalyx degradation amplifies inflammation and capillary leakage in lung injury.
- Preservation strategies and endothelial protection may improve transplant outcomes.

## Abstract

Lung transplantation remains the definitive treatment for selected patients with end-stage respiratory failure; however, outcomes are limited by significant early morbidity and mortality. Primary graft dysfunction (PGD), occurring within the first 72 hours after transplantation, is the most severe early complication and is largely driven by pulmonary ischemia–reperfusion (IR) injury. Growing evidence identifies the pulmonary endothelium as a primary target of IR, with endothelial dysfunction playing a central role in increased vascular permeability, pulmonary edema, impaired gas exchange, and altered pulmonary vascular tone.

During ischemia, endothelial metabolic alterations, oxidative stress priming, and glycocalyx degradation sensitize the pulmonary microvasculature to reperfusion injury. Reperfusion then triggers a marked inflammatory response characterized by reactive oxygen species generation, calcium overload, mitochondrial dysfunction, leukocyte recruitment, and disruption of intercellular junctions, leading to endothelial barrier breakdown and microvascular leakage. The endothelial glycocalyx, a critical regulator of vascular permeability and mechanotransduction, is particularly vulnerable to IR injury, and its degradation further amplifies inflammation and capillary leakage.

This narrative review summarizes the key mechanisms involved in pulmonary IR injury, with a focus on endothelial and glycocalyx dysfunction and their contribution to PGD after lung transplantation. We discuss major pathways involved in vasomotor dysregulation, oxidative stress, and inflammatory signaling, as well as the influence of graft preservation strategies, including cold storage temperature and ex vivo lung perfusion. Finally, we review emerging therapeutic approaches aimed at preserving endothelial integrity and glycocalyx structure.

Targeting endothelial and glycocalyx protection represents a promising strategy to reduce IR-related lung injury and improve post-transplant outcomes.

## Full-text entities

- **Genes:** SGCB (sarcoglycan beta) [NCBI Gene 6443] {aka A3b, LGMD2E, LGMDR4, SGC}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, SLC8A1 (solute carrier family 8 member A1) [NCBI Gene 6546] {aka NCX1}, SDC1 (syndecan 1) [NCBI Gene 6382] {aka CD138, SDC, SYND1, syndecan}, RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MFSD11 (major facilitator superfamily domain containing 11) [NCBI Gene 79157] {aka ET}, NOS1 (nitric oxide synthase 1) [NCBI Gene 4842] {aka IHPS1, N-NOS, NC-NOS, NOS, bNOS, nNOS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, HSPG2 (heparan sulfate proteoglycan 2) [NCBI Gene 3339] {aka HSPG, PLC, PRCAN, SJA, SJS, SJS1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, XDH (xanthine dehydrogenase) [NCBI Gene 7498] {aka XAN1, XDH/XO, XO, XOR}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, PRKG1 (protein kinase cGMP-dependent 1) [NCBI Gene 5592] {aka AAT8, PKG, PKG1, PRKG1B, PRKGR1B, cGK}, PCLAF (PCNA clamp associated factor) [NCBI Gene 9768] {aka KIAA0101, L5, NS5ATP9, OEATC, OEATC-1, OEATC1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, KNG1 (kininogen 1) [NCBI Gene 3827] {aka BDK, BK, HAE6, HK, HMWK, KNG}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** hypercapnia (MESH:D006935), hypoxic (MESH:D002534), brain death (MESH:D001926), Hypoxia (MESH:D000860), Cold ischemia (MESH:D007511), mitochondrial dysfunction (MESH:D028361), calcium overload (MESH:D019190), Inflammatory (MESH:D007249), lung injuries (MESH:D055370), edema (MESH:D004487), PGD (MESH:D055031), pulmonary edema (MESH:D011654), ischemic (MESH:D002545), lung dysfunction (MESH:D008171), endothelial dysfunction (MESH:D014652), aspiration pneumonia (MESH:D011015), sepsis (MESH:D018805), intravascular coagulation (MESH:D004211), hyperlactatemia (MESH:D065906), leukemia (MESH:D007938), IR injury (MESH:D015427), microvascular dysfunction (MESH:D017566), Hypothermia (MESH:D007035), cytotoxic (MESH:D064420), endothelial injury (MESH:D057772), low cardiac output (MESH:D002303), end-stage respiratory failure (MESH:D007676)
- **Chemicals:** Acetylcholine (MESH:D000109), disaccharide (MESH:D004187), IP3 (MESH:D015544), hyaluronan (MESH:D006820), hydroxyl radicals (MESH:D017665), NO (MESH:D009569), xanthine (MESH:D019820), PGI2 (MESH:D011464), L-citrulline (MESH:D002956), propofol (MESH:D015742), Hypoxanthine (MESH:D019271), oxygen (MESH:D010100), keratan sulfate (MESH:D007632), chondroitin sulfate (MESH:D002809), cGMP (MESH:D006152), GTP (MESH:D006160), ADP (MESH:D000244), PIP2 (MESH:D019269), lipid (MESH:D008055), peroxynitrite (MESH:D030421), ATP (MESH:D000255), Calcium (MESH:D002118), ROS (MESH:D017382), 5-HT (MESH:D012701), H+ (MESH:D006859), dermatan sulfate (MESH:D003871), sevoflurane (MESH:D000077149), Na+ (MESH:D012964), K+ (MESH:D011188), GAG (MESH:D006025), heparan sulfate (MESH:D006497), Ca2+ (-), superoxide (MESH:D013481), hydrogen peroxide (MESH:D006861), carbohydrates (MESH:D002241), L-arginine (MESH:D001120), NADPH (MESH:D009249)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A2A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955690/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955690/full.md

## References

61 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955690/full.md

---
Source: https://tomesphere.com/paper/PMC12955690